Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program

Jean Addington; Matthew R. Broome; Jack Rogers; Rachel Upthegrove; Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ)

doi:10.1093/schizbullopen/sgaf012

Abstract

Background
This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables and biomarkers in a total of 2040 clinical high-risk (CHR) participants and 652 community control (CC) participants.

Methods
The dataset analyzed includes 1642 individuals at clinical high risk for psychosis and 519 CCs. Key measures include the Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the Structured Interview for Psychosis-Risk Syndromes, which determined CHR criteria and the severity of attenuated psychotic symptoms (APS). Other measures included the Structured Clinical Interview for DSM-5, scales to assess negative symptoms, depression, suicidal ideation, substance use, social and role functioning, and a selection of patient-reported outcomes.

Results
CHR participants presented with more severe ratings on all clinical measures and poorer functioning relative to the CC. There were a few significant small associations between measures of APS and other clinical measures.

Conclusion
The results from this study support previous research indicating that CHR individuals face serious clinical challenges beyond the risk of developing psychosis. Findings indicate significant associations among various clinical measures, underscoring the complex nature of the CHR population. Limitations are acknowledged, including the preliminary nature of the data and the need for more in-depth analyses from AMP SCZ papers already in progress. Future work will focus on longitudinal data and further exploration of clinical variables and their relationship with biomarkers.

Original language	English
Article number	sgaf012
Number of pages	13
Journal	Schizophrenia Bulletin Open
Volume	6
Issue number	1
Early online date	28 Jan 2025
DOIs	https://doi.org/10.1093/schizbullopen/sgaf012
Publication status	Published - 25 Aug 2025

Bibliographical note

A full list of the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) members and affiliations can be found at https://www.ampscz.org/members/.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/schizbullopen/sgaf012Licence: Creative Commons: Attribution (CC BY)

AddingtonJ2025BaselineFinal published version, 0.99 MBLicence: Creative Commons: Attribution (CC BY)

PRESCIENT: Trajectories and Predictors in the Clinical High Risk for Psychosis Population: Prediction Scientific Global Consortium
Upthegrove, R. (Principal Investigator), Broome, M. (Co-Investigator) & Rogers, J. (Co-Investigator)
NATIONAL INSTITUTE OF HEALTH, USA
8/09/20 → 31/08/27
Project: Research

Cite this

@article{ed8285510ac54e6592f4d4f387ee0c69,

title = "Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program",

abstract = "Background This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables and biomarkers in a total of 2040 clinical high-risk (CHR) participants and 652 community control (CC) participants. Methods The dataset analyzed includes 1642 individuals at clinical high risk for psychosis and 519 CCs. Key measures include the Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the Structured Interview for Psychosis-Risk Syndromes, which determined CHR criteria and the severity of attenuated psychotic symptoms (APS). Other measures included the Structured Clinical Interview for DSM-5, scales to assess negative symptoms, depression, suicidal ideation, substance use, social and role functioning, and a selection of patient-reported outcomes. Results CHR participants presented with more severe ratings on all clinical measures and poorer functioning relative to the CC. There were a few significant small associations between measures of APS and other clinical measures. Conclusion The results from this study support previous research indicating that CHR individuals face serious clinical challenges beyond the risk of developing psychosis. Findings indicate significant associations among various clinical measures, underscoring the complex nature of the CHR population. Limitations are acknowledged, including the preliminary nature of the data and the need for more in-depth analyses from AMP SCZ papers already in progress. Future work will focus on longitudinal data and further exploration of clinical variables and their relationship with biomarkers.",

author = "Jean Addington and Broome, \{Matthew R.\} and Jack Rogers and Rachel Upthegrove and \{Accelerating Medicines Partnership{\textregistered} Schizophrenia (AMP{\textregistered} SCZ)\}",

note = "A full list of the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) members and affiliations can be found at https://www.ampscz.org/members/.",

year = "2025",

month = aug,

day = "25",

doi = "10.1093/schizbullopen/sgaf012",

language = "English",

volume = "6",

journal = "Schizophrenia Bulletin Open",

issn = "2632-7899",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program

AU - Addington, Jean

AU - Broome, Matthew R.

AU - Rogers, Jack

AU - Upthegrove, Rachel

AU - Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ)

N1 - A full list of the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) members and affiliations can be found at https://www.ampscz.org/members/.

PY - 2025/8/25

Y1 - 2025/8/25

N2 - Background This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables and biomarkers in a total of 2040 clinical high-risk (CHR) participants and 652 community control (CC) participants. Methods The dataset analyzed includes 1642 individuals at clinical high risk for psychosis and 519 CCs. Key measures include the Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the Structured Interview for Psychosis-Risk Syndromes, which determined CHR criteria and the severity of attenuated psychotic symptoms (APS). Other measures included the Structured Clinical Interview for DSM-5, scales to assess negative symptoms, depression, suicidal ideation, substance use, social and role functioning, and a selection of patient-reported outcomes. Results CHR participants presented with more severe ratings on all clinical measures and poorer functioning relative to the CC. There were a few significant small associations between measures of APS and other clinical measures. Conclusion The results from this study support previous research indicating that CHR individuals face serious clinical challenges beyond the risk of developing psychosis. Findings indicate significant associations among various clinical measures, underscoring the complex nature of the CHR population. Limitations are acknowledged, including the preliminary nature of the data and the need for more in-depth analyses from AMP SCZ papers already in progress. Future work will focus on longitudinal data and further exploration of clinical variables and their relationship with biomarkers.

AB - Background This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables and biomarkers in a total of 2040 clinical high-risk (CHR) participants and 652 community control (CC) participants. Methods The dataset analyzed includes 1642 individuals at clinical high risk for psychosis and 519 CCs. Key measures include the Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the Structured Interview for Psychosis-Risk Syndromes, which determined CHR criteria and the severity of attenuated psychotic symptoms (APS). Other measures included the Structured Clinical Interview for DSM-5, scales to assess negative symptoms, depression, suicidal ideation, substance use, social and role functioning, and a selection of patient-reported outcomes. Results CHR participants presented with more severe ratings on all clinical measures and poorer functioning relative to the CC. There were a few significant small associations between measures of APS and other clinical measures. Conclusion The results from this study support previous research indicating that CHR individuals face serious clinical challenges beyond the risk of developing psychosis. Findings indicate significant associations among various clinical measures, underscoring the complex nature of the CHR population. Limitations are acknowledged, including the preliminary nature of the data and the need for more in-depth analyses from AMP SCZ papers already in progress. Future work will focus on longitudinal data and further exploration of clinical variables and their relationship with biomarkers.

U2 - 10.1093/schizbullopen/sgaf012

DO - 10.1093/schizbullopen/sgaf012

M3 - Abstract

SN - 2632-7899

VL - 6

JO - Schizophrenia Bulletin Open

JF - Schizophrenia Bulletin Open

IS - 1

M1 - sgaf012

ER -

Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Projects

PRESCIENT: Trajectories and Predictors in the Clinical High Risk for Psychosis Population: Prediction Scientific Global Consortium

Cite this